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Antigen specificity is critical in immune response
and requires integration of antigen-specific signals
with antigen-nonspecific signals such as those
provided by cytokines. The mechanism integrating
these pathways is incompletely understood. We
report here that antigen-specific proliferative
responses of CD4+ T cells required downmodulation
of tumor suppressor p53. In the absence of T cell
receptor (TCR) signal, IL-2 induced sustained
increase in p53 protein, which prevented proliferative
responses despite strong signaling through the
IL-2 receptor. In contrast, TCR signaling resulted
in early termination of p53 protein expression by
decreasing p53 mRNA as well as strong tran-
scriptional induction of the p53-regulating protein
Mdm2. Downmodulation of p53 in response to
antigen stimulation was in fact critical for antigen-
specific T cell proliferation, and preventing p53
degradation by inhibiting Mdm2 resulted in sus-
tained p53 protein and prevented antigen-specific
T cell proliferation. It is thus termination of p53 by
TCR signaling that allows proliferative responses,
enforcing antigen specificity.
INTRODUCTION
The physiologic stimuli that signal activation of T cells include
antigen-specific stimuli delivered through the T cell receptor
(TCR) (Smith-Garvin et al., 2009) and antigen-nonspecific signals
such as those provided by cytokines (Schluns and Lefranc¸ois,
2003). These classes of T cell signals can be interactive, for
example through the ability of TCR engagement to upregulate
cytokine receptors (Kim and Leonard, 2002), resulting in cooper-
ativity between antigenic and cytokine stimuli in the induction of
proliferative and differentiative responses (Boyman and Sprent,
2012; Constant and Bottomly, 1997; Yamane and Paul, 2013).
However, themechanisms that regulate cooperative interactions
and determine the responsiveness of T cells to these diverse
stimuli are incompletely understood.
In the adaptive immune system, T and B lymphocytes pro-
liferate extensively after recognition of antigen via TCR orBCR, respectively, increasing the number of antigen-specific
T or B lymphocytes, a process of clonal expansion that allows
the immune system to rapidly respond to antigenic challenges
(Jenkins et al., 2001; McHeyzer-Williams and McHeyzer-Wil-
liams, 2005). Antigen-nonspecific cytokines cooperate with
antigen receptor signals in these responses to support pro-
liferation and differentiation of antigen-specific cells (Boyman
and Sprent, 2012; Schluns and Lefranc¸ois, 2003). After the
encounter of a naive or antigen-inexperienced T cell with
specific antigen, initial clonal expansion is followed by the
appearance of differentiated memory T cells (Harty and Bado-
vinac, 2008; van Leeuwen et al., 2009), which retain antigen
specificity and have acquired the capacity for rapid reacti-
vation, proliferation, and expression of effector activity.
Memory T cells proliferate in the periphery, and this self-
renewal of memory T cells is a mechanism for maintaining
their pool size for long periods of time, supporting persistence
of immunological memory (Surh and Sprent, 2008). The
specific contributions of cytokine and TCR-driven signals in
naive and memory cell responses and homeostasis remain
uncertain.
In the present study, we have identified a critical role of p53
in antigen-specific responses of CD4+ T cells. p53 is well known
as a tumor suppressor that functions to prevent tumor develop-
ment and growth through induction of cell cycle arrest, senes-
cence, and/or apoptosis in response to abnormal oncogene
activation or DNA damage (Kruse and Gu, 2009; Vousden and
Prives, 2009). Less is known about the physiological role of
p53 in regulating proliferation of normal cells in response to
diverse signals. We found that p53 had a profound impact on
CD4+ T cell proliferation and that this impact was highly selec-
tive. Both primary and memory antigen-specific proliferative
responses of CD4+ T cells required downmodulation of p53.
Stimulation with interleukin-2 (IL-2) in the absence of con-
comitant antigen-specific TCR stimulation induced sustained
increases in p53 protein expression, and proliferation did not
occur under this condition. In contrast, TCR stimulation
suppressed p53 mRNA and induced expression of the p53-
specific ubiquitin ligase Mdm2, thus limiting the duration of
p53 protein expression and allowing only antigen-specific
T cell proliferation. This downregulation of p53 was necessary
for antigen-specific responses of naive and antigen-primed
peripheral T cells and T cell clones. These findings indicate
that p53 plays a critical and previously unappreciated role in
integrating growth signals to selectively support antigen-specific
T cell proliferation.Immunity 40, 681–691, May 15, 2014 ª2014 Elsevier Inc. 681
Figure 1. Antigen-Specific Trp53–/–, but Not WT, CD4+ T Cell Clones
Proliferate in Response to IL-2 in the Absence of Antigenic Stimula-
tion
(A)WT and Trp53/KLH-specific CD4+ T cell cloneswere cultured for 10 days
under indicated conditions. Fold expansion was calculated as (recovered cell
number/initial cell number). Mean ± SEM is shown (three clones per genotype).
The data are representative of at least three independent experiments.
(B) IL-2 dose response for cell expansion of WT and Trp53/ CD4+ T clones.
Three clones each of WT and Trp53/ were stimulated under indicated
conditions for 10 days and fold expansion was calculated. The graph is
representative of two independent experiments.
(C) Kinetic analysis of fold expansion of CD4+ T clones. Three clones each of
WT and Trp53/ were stimulated with Ag-APC + IL-2 or IL-2 alone, and fold
expansion at indicated time points was calculated. The graph is representative
of three independent experiments.
(D) Three clones each of WT and Trp53/ were stimulated with IL-2 alone for
10 days in 3 consecutive cycles without Ag-APC stimulation. Fold expansion
was calculated at the end of each cycle. The graph is mean ± SEM and
representative of at least three independent experiments.
(E) KLH-specific CD4+ T cell clones established from p53ER-TAM mice were
stimulated with Ag-APC + IL-2 or IL-2 alone in the presence or absence of
4-hydoroxy-tamoxifen (4-OHT) for 10 days and fold expansion was calculated.
The data are representative of three independent experiments.
*p < 0.05; **p < 0.01. See also Figure S1.
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p53 Inhibits IL-2-Driven Proliferation in the Absence of
Antigen-Specific Stimulus
An effective immune system requires a high degree of antigen
specificity in responses of T cells to specific antigens. However,
T cells can also be driven to proliferate by antigen-nonspecific
signals such as those provided by cytokines. Integration of these
signals is therefore essential to maintain antigen specificity of
response. We have tested the possibility that tumor suppressor
p53, a regulator of cell cycle and cell survival, might play a role in
the responses of antigen-specific T cells. To characterize the
role of p53 in regulating antigen-specific and antigen-nonspe-
cific cytokine-driven T cell responses, we first analyzed anti-
gen-specific CD4+ T cell clones generated from Trp53/ and
littermate Trp53 WT mice. Proliferation of Trp53/ and WT
clones was equivalent after stimulation with specific antigen
(KLH) plus antigen-presenting cells (APCs) in the presence of
recombinant IL-2 (Figure 1A). Exogenous IL-2 was required for
antigen-specific proliferation because of the limiting amount of
endogenous IL-2 produced by these clones. Although WT and
Trp53/ clones were equivalently responsive to IL-2 in the pres-
ence of antigen-specific signals (Figures 1A and 1B, left), a strik-
ing difference was seen in their responses to IL-2 in the absence
of antigen (Figures 1A and 1B, right). Trp53/ clones prolifer-
ated strongly to higher concentrations of IL-2 alone at a magni-
tude of response comparable to their response to Ag-APC +
IL-2, whereas WT clones exhibited very limited expansion (Fig-
ures 1A and 1B). Similar patterns were observed for multiple
KLH-specific WT and Trp53/ clones (Figures 1A and 1B) as
well as for uncloned OVA-specific WT and Trp53/ CD4+
T cell lines (Figure S1A available online). This differential effect
of p53 on T cell responses was sustained over a time course of
proliferative response (Figure 1C). These results indicate that
WTCD4+ cells proliferate in response to IL-2 only in the presence
of TCR signals, whereas Trp53/ clones respond to IL-2
in either presence or absence of antigen. This difference in
Figure 2. p53 Does Not Affect Proximal IL-2 Receptor Signaling
(A) IL-2 receptor expression of CD4+ T cell clones at resting state was analyzed
by flow cytometry. In histograms, solid lines indicate specific staining and
dashed lines indicate isotype control staining. The graphs are mean ± SEM of
three clones each of WT and Trp53/ and are representative of three inde-
pendent experiments. n.s., no significant difference.
(B) Induction of Stat5 phosphorylation upon IL-2 stimulation was analyzed by
flow cytometry. Resting WT and Trp53/clones were stimulated with IL-2
(100 U/ml) for 15 min and then analyzed. In histograms, solid lines indicate
pStat5 (Y694) staining of IL-2-stimulated cells and dashed lines indicate
staining of unstimulated cells. The graph presentsmean ± SEM of three clones
each of WT and Trp53/ and is representative of three independent experi-
ments.
(C) Induction of Akt phosphorylation upon IL-2 stimulation was analyzed by
flow cytometry. Resting WT and Trp53/ clones were stimulated with IL-2 for
15 min and then analyzed. In histogram, solid lines indicate pAkt (S473)
staining of IL-2-stimulated cells and dashed lines indicate staining of
unstimulated cells. The graph presents mean ± SEM of three clones each of
WT and Trp53/ and is representative of three independent experiments.
(D) Induction of CD25 expression upon IL-2 stimulation. Resting WT and
Trp53/ clones were stimulated with IL-2 for 24 hr and then CD25 expression
was analyzed by flow cytometry. Gray filled histograms indicate CD25 staining
of IL-2-stimulated cells, open histograms indicate staining of unstimulated
cells, and dashed lines indicate isotype control staining. The graph presents
mean ± SEM of three clones each of WT and Trp53/ and is representative of
three independent experiments.
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for multiple IL-2 stimulation cycles (Figure 1D), indicating that
recent Ag stimulation was not required for IL-2 responsiveness
of Trp53/ T cells.
The observed differences between WT and constitutively
Trp53/ clones could reflect the direct effect of p53 absence
or the secondary consequences of long-term p53 deficiency,
for example through accumulation of mutations or epigenetic
changes secondary to absence of p53. To address this possi-
bility, we generated T cell clones from genetically targeted
p53ER-TAM mice (Christophorou et al., 2005) that express a
p53-estrogen receptor fusion protein, p53ER, which can translo-
cate to the nucleus and exert its p53 functions only in the pres-
ence of 4-hydroxy-tamoxifen (4-OHT, TAM). The proliferative
responses of p53ER-TAM clones to antigen stimulation were
similar in the presence of 4-OHT (p53 active) or in its absence
(p53 inactive) (Figure 1E, left). In contrast, addition of 4-OHT
(p53 active) resulted in suppression of T cell proliferation in
response to IL-2 alone (Figure 1E, right). 4-OHT had no effect
on the responses of constitutive Trp53/ clones to IL-2 alone,
confirming the specificity of its effect (Figure S1B). It is thus the
presence of functional p53 that acts to prevent cytokine-driven
antigen-nonspecific T cell proliferation but does not inhibit re-
sponses to IL-2 in the presence of specific antigen stimulus.
p53 Does Not Affect Proximal IL-2 Receptor Signaling
Wenext pursued themechanismbywhich p53 prevents antigen-
independent IL-2-induced T cell proliferation. We first asked
whether the difference in response to IL-2 by WT and Trp53/
cells could be explained by differences in IL-2 receptor (IL-2R)
complex expression or proximal signaling. The IL-2R complex
is composed of CD25 (a), CD122 (b), and CD132 (gc) molecules.
Cell surface expression of CD25, CD122, and CD132 was not
significantly different between WT and Trp53/ T cells prior to
IL-2 stimulation (Figure 2A). IL-2R signaling proceeds throughImmunity 40, 681–691, May 15, 2014 ª2014 Elsevier Inc. 683
Figure 3. p53 Suppresses Cell Cycle Pro-
gression in Response to Stimulation with
IL-2 Alone
(A) DNA synthesis of CD4+ clones upon IL-2 stimu-
lation. WT and Trp53/ clones were stimulated
with IL-2 (100 U/ml), and DNA synthesis at indicated
time points was analyzed by measuring [3H]thymi-
dine incorporation. The result is representative of
three independent experiments.
(B) Cell cycle progression of CD4+ clones upon IL-2
stimulation. WT and Trp53/ clones were stimu-
lated with IL-2, and DNA content at indicated time
points was analyzed by propidium iodide (PI)
staining. The result is representative of two inde-
pendent experiments.
(C) Cell division of CD4+ clones upon IL-2 stimula-
tion. WT and Trp53/ clones were stained with
CFSE and cultured under indicated conditions for
10 days. CFSE dilutionwas analyzed to evaluate cell
division by flow cytometry. The graph indicates
percent of cells dividing more than two times as
mean ± SEM of three clones each of WT and
Trp53/. The result is representative of three
independent experiments.
(D) Cell death of CD4+ clones upon IL-2 stimulation.
WT and Trp53/ clones were stimulated with IL-2
for 48 hr. Percent dead cells were evaluated with
AnnexinV and PI staining by flow cytometry. The
graphs shown are mean ± SEM of three clones each
of WT and Trp53/ and representative of two
independent experiments.
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respectively (Liao et al., 2013). Phosphorylation of Stat5 and
Akt after stimulation with IL-2 was measured by flow cytometric684 Immunity 40, 681–691, May 15, 2014 ª2014 Elsevier Inc.quantitation and was found to be compa-
rable between WT and Trp53/ (Figures
2B and 2C). CD25 induction after IL-2 stim-
ulation was also analyzed because CD25
expression is known to be a target of
IL-2R signaling (Kim et al., 2001). CD25
upregulation was not significantly different
between WT and Trp53/ clones (Fig-
ure 2D). These results indicate that prox-
imal IL-2R signaling pathways are not
affected by the presence of p53 and that
differences in IL-2R signaling therefore do
not account for the differential proliferative
response of Trp53/ but not WT T cells to
IL-2 stimulation.
p53 Blocks Cell Cycle Progression in
Response to IL-2
Because p53 is known to prevent cell cycle
progression and to induce apoptosis in
response to DNA damage and oncogenic
signals, we tested whether these mecha-
nisms are also involved in prevention of
IL-2-induced T cell expansion. First, DNA
synthesis was evaluated by [3H]thymidine
uptake. Whereas WT clones showed nosignificant DNA synthesis at any time point, Trp53/ clones
showed substantial DNA synthesis during days 3–7 after IL-2
stimulation (Figure 3A). Similar results were obtained for cell
Figure 4. Antigen Stimulation Downmodu-
lates p53 Expression Induced by IL-2
(A) WT clones were stimulated for 48 hr (top) and for
the indicated times up to 96 hr (bottom), and p53
protein was analyzed by immunoblotting. b-actin
was used as internal control. The data are repre-
sentative of three independent experiments.
(B) WT and Trp53/ clones were stimulated as
indicated for 96 hr and p53 protein expression was
analyzed by flow cytometry. Trp53/ clones were
used as a negative control for p53 staining. Results
are representative of three independent experi-
ments.
(C) Statistical analysis of the results shown in (B).
The graph presents means ± SEM of three clones
each of WT and Trp53/ and representative of
three independent experiments.
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clones showing increasing proportions of cells in S and G2-M
phase after IL-2 stimulation, with peaks at day 4–8, whereas
WT clones showed only small increases of cells in S phase (Fig-
ure 3B). Analysis of cell division by CFSE dye dilution similarly
showed extensive and equivalent cell division in WT and
Trp53/ clones in response to Ag-APC + IL-2, whereas
Trp53/ but not WT clones underwent extensive division to
IL-2 alone (Figure 3C). We also used AnnexinV-PI staining to
measure T cell death after IL-2 stimulation (Figure 3D). IL-2 stim-
ulation protectedWT aswell as Trp53/ cell from apoptosis that
occurred in the absence of added cytokine, and there was no
significant difference in proportion of apoptotic cells between
WT and Trp53/ clones in response to IL-2 (Figure 3D). TheseImmunity 40, 681results indicate that p53 inhibits IL-2-
driven proliferation by cell cycle blockade.
p53 Protein Expression Is
Differentially Regulated by Antigen
and IL-2 Stimulation
The observations to this point indicated
that intact p53 prevents the proliferative
response of CD4+ T cells to IL-2 in the
absence of antigenic stimulation but does
not inhibit responses to IL-2 in the pres-
ence of antigenic stimulation. To address
the mechanism underlying this differential
effect, we asked whether p53 protein
expression was differentially regulated in
CD4+ T cell clones after stimulation with
IL-2 alone, Ag-APC, or Ag-APC + IL-2.
After 48 hr, p53 protein was increased in
each of these stimulation conditions (Fig-
ure 4A, top). Notably, however, although
early induction of p53 protein was similar
in response to all stimuli, p53 protein
decreased substantially by 72 hr and was
nearly returned to prestimulation amounts
by 96 hr in Ag-APC + IL-2-stimulated
clones, whereas induced p53 protein
expression was sustained after stimulationwith IL-2 alone through 96 hr (Figure 4A, bottom). Similar results
were obtained when p53 protein expression was examined at
the single cell level by flow cytometry (Figures 4B and 4C). These
results indicate that p53 protein is differentially regulated by
antigen-specific and IL-2-mediated stimulation, with TCR-medi-
ated antigen stimulation terminating p53 expression.
To assess the basis for p53 regulation in response to T cell
stimulation, we first measured p53 mRNA by quantitative PCR.
p53 mRNA was transiently elevated 24 hr after stimulation with
IL-2 alone and then returned to prestimulation baseline. In
contrast, after Ag-APC + IL-2 stimulation, p53 mRNA expression
was not elevated and by 96 hr was significantly lower than that of
prestimulation cells (Figure 5). It is known that p53 protein
expression is also regulated posttranscriptionally after DNA–691, May 15, 2014 ª2014 Elsevier Inc. 685
Figure 5. Antigen Stimulation InducesMdm2 and Termination of p53
Expression
Trp53 and Mdm2 mRNA expression upon stimulation with Ag-APC + IL-2 or
IL-2 alone. KLH-specific clones were stimulated as indicated. mRNA
expression wasmeasured by real-time qPCR and normalized toGapdhmRNA
expression. The graphs are mean ± SEM of three WT clones and represen-
tative of three independent experiments.
Figure 6. Nutlin3a Prevents Downmodulation of p53 and Inhibits
Antigen-Specific Proliferation of WT but Not Trp53–/– T Cell Clones
(A) Nutlin3a inhibits downmodulation of p53 protein expression after Ag-APC +
IL-2 stimulation. KLH-specificWTCD4+ cloneswere stimulated with Ag-APC +
IL-2 with or without Nutlin3a (5 mM) for 96 hr, and p53 protein expression was
measured by flow cytometry.
(B) The effect of Nutlin3a on cell expansion of KLH-specific CD4+ T clones.
Three WT and three Trp53/ clones were stimulated with Ag-APC + IL-2 for
8 days in the presence of Nutlin3a (5 mM) and fold expansion was calculated.
The graph is mean ± SEM of three clones each of WT and Trp53/ and is
representative of three independent experiments.
(C) The effect of Nutlin3a on cell expansion of OVA-specific CD4+ T lines. WT
and Trp53/ lines were stimulated with OVA323-339-APC + IL-2 with or without
Nutlin3a (5 mM) for 8 days and fold expansion was calculated. The result is
mean ± SEM of pool data of two independent experiments.
*p < 0.05; **p < 0.01.
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ubiquitination and proteasomal degradation (Kruse and Gu,
2009). We therefore examined the effect of IL-2 stimulation, in
the presence or absence of antigenic stimulus, on expression
of Mdm2. Ag-APC + IL-2 stimulation but not IL-2 alone strongly
inducedMdm2mRNA expression to approximately 50 times that
of prestimulation cells (Figure 5). This effect was seen by 48 hr
and persisted through at least 96 hr. These results suggest
that downmodulation of p53 protein upon Ag-APC + IL-2 stimu-
lation was the consequence of both decreased p53 mRNA and
increased Mdm2-mediated proteolysis.
Downmodulation of p53 Is Required for Antigen-Specific
T Cell Proliferation
The finding that p53 protein was downmodulated by stimulation
with Ag-APC + IL-2 but persisted after stimulation with IL-2 alone
suggested that this downmodulation of p53 protein might be
critical to induction of antigen-specific proliferation in WT
T cells. We therefore tested whether inhibition of Mdm2 would
prevent downregulation of p53 protein after Ag-APC + IL-2
stimulation, allowing assessment of the importance of p53
downregulation for T cell proliferative responses. Although p53
downregulation occurred in Ag-APC + IL-2-stimulated T cells
by 96 hr (Figures 4B and 4C), in the presence of Nutlin3a, which
inhibits Mdm2-p53 interaction and prevents Mdm2-mediated
p53 protein degradation (Vassilev et al., 2004), downmodulation
of p53 protein in Ag-APC + IL-2-stimulated clones was not
observed at 96 hr (Figure 6A). We therefore tested whether
preventing p53 downmodulation after Ag-APC + IL-2 stimulation
would indeed prevent T cell proliferation.
Strikingly, Nutlin3a strongly inhibited the proliferation of KLH-
specific WT clones stimulated with KLH-APC + IL-2 but had no
effect on the responses of Trp53/ clones to the same stimula-
tion (Figure 6B). A similar effect was observed when WT or
Trp53/OVA-specific T cell lines were stimulated with
OVA323-339-APC + IL-2 in the presence or absence of Nutlin3a
(Figure 6C). These results indicate that downmodulation of p53686 Immunity 40, 681–691, May 15, 2014 ª2014 Elsevier Inc.is critical for T cell proliferation and that the ability of antigen-
specific stimulation to induce IL-2 responsiveness and antigen-
specific proliferation requires termination of p53 expression.
Downmodulation of p53 Is Required for Antigen-Specific
Proliferation of Naive or In Vivo Primed T Cells
These results suggested that regulation of p53 might play a
critical role in the physiologic responses of T cells to TCR-medi-
ated antigen-specific challenge. It was therefore important to
determine whether p53 plays a role in regulating antigen-specific
Immunity
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memory CD4+ T cells, as was shown for cell lines. Kinetic
patterns of p53 expression and proliferation of CD4+ T cells
were first analyzed in response to in vivo Ag stimulation. OVA-
specific OT-II cells were adoptively transferred to congenic
CD45.1 mice followed by NP-OVA-Alum immunization. Upregu-
lation of p53 protein in OT-II cells was observed on day 2 after
immunization, but p53 was drastically downmodulated at day
3–4, during which time extensive OT-II clonal expansion
occurred (Figure 7A), consistent with the pattern observed in
KLH-specific CD4+ T cell clones (Figures 4B–4D). Similarly, upre-
gulation of p53 expression in in vitro Ag-stimulated naive OT-II
cells was observed at day 3, followed by downmodulation of
p53 by day 5, during which time extensive clonal expansion of
OT-II cells occurred (Figure 7B). Therefore we next determined
whether the primary proliferative responses of unprimed T cells
are dependent upon downmodulation of p53. Responses of
unprimed p53 WT OT-II cells to specific antigen were strongly
inhibited by Nutlin3a, whereas responses of Trp53/ cells
were unaffected (Figure 7C). Nutlin3a also inhibited proliferation
of p53 WT CD4+ T cells in response to anti-CD3 TCR-specific
stimulation (Figure 7D).
We next determined whether proliferative responses of in vivo
primed CD4+ T cells are similarly dependent upon downmodula-
tion of p53. Antigen-primed T cells were generated by adoptive
transfer of Trp53/ or p53-intact OVA-specific OT-II TCR
transgenic T cells into Rag1/ mice and priming with OVA-
Alum 1 day after transfer. Three to four weeks later, splenic
CD4+ T cells were recovered and challenged in vitro with OVA
in the presence or absence of Nutlin3a. OT-II T cells were at
this point uniformly CD44hiCD62LloCD25 memory phenotype
(Figure S2). In the absence of Nutlin3a, Trp53/ and p53-intact
memory OT-II T cells proliferated vigorously and equivalently in
response to OVA (Figure 7E). Addition of Nutlin3a had no effect
on the response of Trp53/ T cells but strongly inhibited
responses of p53-intact OT-II cells. Similar results were obtained
for proliferation of naturally occurring nontransgenic memory
phenotype (CD44hiCD62LloCD25) peripheral CD4+ T cells in
response to anti-CD3 TCR-specific stimulation (Figure 7F).
Thus, the antigen-specific responses as well as anti-CD3-
induced TCR-specific responses of unprimed and in vivo primed
CD4+ T cells are dependent upon downmodulation of p53.
DISCUSSION
The studies reported here identify a central role of p53 in
regulating the antigen-specific responses of T lymphocytes.
The ability of wild-type naive or memory CD4+ T cells or T cell
clones to proliferate in response to TCR stimulation was strictly
dependent upon downregulation of p53 protein. This was
accomplished by the ability of TCR signaling to induce termina-
tion of an initial increase of p53 protein expression by both
decreasing p53 mRNA and markedly increasing transcription
of Mdm2, which mediates posttranscriptional inactivation of
p53 (Kruse and Gu, 2009). Nutlin3a prevents p53 downmodula-
tion by inhibiting p53-Mdm2 interaction and resulted in inhibition
of antigen-specific and TCR-mediated proliferation by p53 wild-
type but not p53-deficient T cells. The unique ability of TCR
signaling to downregulate p53 acts to prevent proliferative re-sponses to antigen-nonspecific signals in the absence of spe-
cific antigen and to thereby enforce the antigen specificity of
T cell proliferation and clonal expansion that is a hallmark of
the adaptive immune system.
The work reported here indicates a central role of p53 in
enforcing the antigen specificity of T cell proliferative responses,
even when these responses are cytokine dependent. Wild-type
CD4+ T cell clones, with intact p53, failed to proliferate in
response to IL-2 in the absence of antigen-specific TCR stim-
ulus, despite the presence of strong proximal IL-2 receptor
signaling. However, in the presence of a TCR stimulus, these
T cells gave strong IL-2-dependent proliferative responses. We
found that this TCR dependence of CD4+ T cell clone responses
to IL-2 is mediated by p53. Trp53/ and WT T cells proliferated
comparably in response to IL-2 in concert with antigen-specific
TCR signals. In marked contrast, p53-deficient but not WT
T cell lines were capable of strong responses to IL-2 alone,
without TCR stimulus. These findings suggested that p53 inhibits
T cell proliferative responses to cytokine, but that this inhibition is
overcome by antigen-specific TCR signaling. We indeed found
that stimulation with IL-2 alone induced a strong and sustained
increase in p53 protein expression. In contrast, stimulation with
Ag-APC + IL-2 induced only transient increases in p53 protein,
terminated by marked downregulation to prestimulation base-
line. These findings suggested that sustained expression of
p53 prevents responses of WT T cells to IL-2 and that antigen-
specific TCR stimulation overcomes this block by causing termi-
nation of the p53 response. Consistent with this model, the
proliferative responses of naive CD4+ T cells to TCR stimulation,
as well as the responses of in vivo primed T cells or T cell lines to
specific antigen, were strongly inhibited when downregulation of
p53 was prevented and upregulated p53 was maintained by
inhibition of Mdm2. It is thus the termination of p53 elevation
by TCR-dependent signaling that allows proliferative response
to occur, favoring antigen specificity over nonspecific bystander
responses.
The role of p53 in immune responses, and specifically in T cell
responses, has been unclear. It was reported that antigen-
specific T cell clonal expansion in responses to foreign antigen,
such as lymphocytic choriogmeningitis virus (LCMV) infection or
sheep red blood cell (SRBC) immunization, was not substantially
affected by the absence of p53 in Trp53/ mice (Grayson et al.,
2001; Ohkusu-Tsukada et al., 1999). Other reports showed that
Trp53/ mice exhibited exaggerated phenotypes in T-cell-
dependent autoimmune models (Okuda et al., 2003; Simelyte
et al., 2005; Zheng et al., 2005) and enhanced antitumor
response (Singh et al., 2010), although the T-cell-intrinsic role
of p53 was not extensively addressed in these studies. Recently
it has been reported that aged T-cell-specific Trp53/ mice
develop an autoimmune phenotype (Kawashima et al., 2013),
indicating a role of p53 for regulation of T cell response. Our
results reported here demonstrate that p53 expression and
function are tightly regulated during antigen-specific T cell prolif-
erative responses, because of the ability of TCR signaling to
terminate p53 expression and consequently permit antigen-
specific clonal expansion. It has been reported that p53 expres-
sion is downregulated in germinal center (GC) B cells, a B cell
subset that undergoes massive clonal expansion and class
switch- and somatic hypermutation-related DNA breakImmunity 40, 681–691, May 15, 2014 ª2014 Elsevier Inc. 687
Figure 7. Downmodulation of p53 Is Necessary for Antigen-Specific Proliferation by Naive or Memory CD4+ T Cells
(A) p53 expression is initially upregulated, followed by downmodulation after in vivo antigen stimulation of CD4+ T cells. OT-II CD4+ T cells were adoptively
transferred to CD45.1 mice followed by NP-OVA-Alum immunization. Cell number and p53 expression of OT-II cells were analyzed at the indicated time points.
The graph is mean ± SEM (n = 3) and is representative of two independent experiments (total n = 5 mice analyzed individually).
(B) p53 expression is initially upregulated, followed by downmodulation after in vitro antigen stimulation of naive OT-II CD4+ T cells. Naive OT-II CD4+ T cells were
stimulated with OVA323-339-APC in vitro, and then cell number and p53 expression of OT-II cells were analyzed at the indicated time points. The data are
representative of three independent experiments.
(C) Naive WT or Trp53/OT-II CD4+ T cells were stimulated with OVA323-339-APC for 96 hr. Nutlin3a was added to the culture as indicated concentration at 24 hr
after stimulation. Recovered live cell numbers are shown. The result is mean ± SEM of pool data of four independent experiments.
(D) Naive B6 CD4+ T cells were stimulated with anti-CD3-APC for 96 hr. Nutlin3a was added to culture as indicated concentration at 24 hr after stimulation.
Recovered live cell numbers are shown. The result is mean ± SEM of pool data of three independent experiments.
(E) OT-II memory T cells were generated in vivo as described in Experimental Procedures and restimulated with OVA323-339-APC for 96 hr. Nutlin3a (2.5 mM) was
added to the culture at 24 hr after stimulation. Representative result of recovered cell numbers is shown after stimulation with antigen in the presence or absence
(legend continued on next page)
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p53 Enforces Antigen Specificity of T Cell Responsesresponses in the process of antigen-driven selection (Phan and
Dalla-Favera, 2004). In the case of GC B cells, the transcription
factor Bcl6, which is highly expressed in GC B cells, represses
p53 transcription and downregulates p53 expression (Phan
andDalla-Favera, 2004).We found that TCR-dependent stimula-
tion of CD4+ T cells with specific antigen resulted in decreased
p53 mRNA, as well as a very large increase in Mdm2 mRNA.
These results suggest that Mdm2-dependent posttranslational
mechanisms as well as suppression of p53 transcription
contribute to the termination of elevated p53 protein expression
by TCR stimulation.
In addition to Mdm2, it is known that the Mdm2-related gene
product Mdm4 (also known as Mdmx) interacts with p53 protein
to inhibit p53 function (Wade et al., 2010, 2013). However,
Nutlin3a is known to more effectively inhibit p53-Mdm2 inter-
action than p53-Mdm4 interaction because Nutlin3a binds with
higher affinity to Mdm2 than to Mdm4 (Wade and Wahl, 2009).
Thus, the nearly complete inhibition by Nutlin3a of proliferation
of T cell clones and naive CD4+ T cells suggests that the role
of Mdm4 is limited in these cells. However, a contribution of
Mdm4 cannot be ruled out, especially in memory CD4 response,
where inhibition of proliferation by Nutlin3a was less complete.
Similarly, p73 and p63 proteins are known p53-related gene
products that show transcriptional activity similar to that of p53
(Do¨tsch et al., 2010; Yang and McKeon, 2000). p73 interacts
with Mdm2 and Mdm4 with an affinity similar to that of p53,
whereas p63 binding affinity to Mdm2 and Mdm4 is much
weaker than that of p53 and p73 (Zdzalik et al., 2010). It is thus
possible that Nutlin3a could inhibit p73-Mdm2 interaction and
induce increases in p73 in addition to p53 activity. However,
the contribution of p73 to inhibition of T cell proliferation, if any,
seems very limited in the conditions that we have studied,
because Nutlin3a showed only limited effect on Trp53/
T cells under conditions in which WT T cell proliferation was
effectively inhibited (Figures 7C–7F). Therefore, although we
cannot completely rule out possible involvement of Mdm4 for
p53 regulation and/or p73 for suppression of T cell proliferation
in this study, Mdm2-mediated p53 regulation appears to be of
predominant importance for controlling antigen-specific T cell
proliferation.
Factors in addition to Mdm2 might play a role in regulation of
p53 protein expression or function. It is known, for example,
that ATM kinase, activated upon DNA damage response, medi-
ates phosphorylation of Ser15 and Ser20 residues of p53,
affecting Mdm2 interaction with p53 (Kruse and Gu, 2009). Arf
(p19) protein, an alternative reading frame product of theCdkn2a
locus, is another upstreammolecule known to activate p53 in the
presence of aberrant activation of oncogenes such as c-myc,
Ras, or E2F (Chen et al., 2010; Sherr, 2006). Arf binds to
Mdm2 and inhibits Mdm2 E3 ubiquitin ligase function resulting
in p53 stabilization (Sherr, 2006). Thus it was possible that IL-2
signals might induce Arf as a mechanism for upregulating p53of Nutlin3a (left). Inhibitory effect of Nutlin3a for antigen-specific memory T cell p
SEM of pool data of three independent experiments (total WT; n = 10, Trp53/;
(F) Peripheral naturally occurring memory phenotype C57BL/6 CD4+ T cells (CD4
added to the culture as indicated at 24 hr after stimulation. Recovered cell num
experiments.
*p < 0.05; **p < 0.01. See also Figure S2.protein expression. However, KLH-specific Atm/ or
Cdkn2a/ (Arf-specific ablation) CD4+ T cell clones failed to
recapitulate the Trp53/ phenotype of long-term proliferative
response to IL-2 alone (unpublished data). Therefore, in this
experimental setting, ATM or Arf is not essential for functional
activity of p53. It will similarly be of interest to determine the
mechanisms downstream of p53 that are involved in prevention
of IL-2-induced T cell proliferation. We found that KLH-specific
CD4+ T cell clones deficient in p21 (Cdkn1a/), p27
(Cdkn1b/), or Ink4a (Cdkn2a/; Ink4a-specific ablation),
known to be p53 target genes and/or regulators of cell cycle,
failed to recapitulate the Trp53/ T cell phenotype of respon-
siveness to IL-2 in absence of antigenic stimulus (unpublished
data). These results may reflect the presence of redundant
pathways that compensate for loss of single genes that act
downstream of p53 to mediate p53 function. Indeed, none of
the gene-ablated strains that we have tested here, when char-
acterized by others, recapitulate the phenotype of Trp53/
mice for susceptibility to spontaneous tumor development
(Deng et al., 1995; Fero et al., 1996; Krimpenfort et al., 2001;
Sharpless et al., 2001). It has been recently proposed that the
p53 target genes responsible for tumor suppression in vivo are
actually different from the classical p53 target genes that are
induced and have been characterized upon acute DNA damage
responses (Brady et al., 2011).
Our data indicate that p53 has a role in preventing CD4+ T cell
proliferation in response to IL-2 in the absence of antigen-
specific TCR signals, potentially limiting bystander proliferation
of nonrelevant T cells. Cytokine-driven bystander proliferation
of memory T cells requires regulation because unnecessary
proliferation could result in accelerated exhaustion of memory
T cells as well as competition with naive T cells or with anti-
gen-specific T cells during an immune response, for example
through competition for limited availability of cytokines essential
for survival. Our results showed that p53 induced by IL-2 sup-
pressed cell cycle progression but did not exhibit a proapoptotic
effect. Therefore, in response to IL-2 and potentially other cyto-
kine growth factors, p53 may function to minimize bystander
proliferation of nonrelevant memory CD4+ T cells, without
affecting cell survival, in order to preserve functional memory
T cells without their exhaustion. The ability of TCR signaling to
induce Mdm2 and to downmodulate p53 protein expression
may also be relevant to the role of p53 as a tumor suppressor.
It has been reported that a number of T cell lymphomas show
evidence of ongoing TCR signaling pathway activity (Warner
et al., 2013), and it is possible that this represents a mechanism
for suppressing p53 as one component of growth dysregulation
and malignant transformation, a possibility that requires further
experimental testing.
The studies presented here provide insight into mechanisms
that integrate TCR and cytokine signals to determine the
outcome of T cell response, identifying a central role of p53 inroliferation is shown as percent inhibition (right). The results shown are mean ±
n = 5).
4hiCD62LloCD25) were stimulated with anti-CD3-APC for 96 hr. Nutlin3a was
bers are shown. The result is mean ± SEM of pool data of three independent
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p53 Enforces Antigen Specificity of T Cell Responsesthis process. IL-2 and antigen-specific signals interact through
regulation of p53 protein expression. The mechanism mediating
this interaction involves the ability of TCR-mediated antigenic
signals, but not IL-2, to induce decreased p53 transcription as
well as vigorous upregulation of Mdm2. These effects mediate
the termination of a transient elevation in p53 and are required
for antigen-specific proliferative responses, as evidenced by
the demonstration that inhibition of Mdm2 results in a sustained
increase in p53 protein and a p53-dependent inhibition of TCR-
dependent primary T cell responses as well as antigen-specific
response of in vivo primed T cells or T cell lines. Regulation of
p53 thus plays a central role in preferentially allowing proliferative
responses by those T cells that encounter specific antigenic
challenge in association with growth factor stimulus, resulting
in antigen-specific T cell clonal expansion.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 p53 genetically ablated heterozygous (Trp53+/) mice were
purchased from Jackson laboratory and maintained in our animal facility to
generate WT (Trp53+/+) and p53-deficient (Trp53/) mice used in the studies
reported here. p53ER-TAM genetically targeted mice were obtained from G.
Evan (Christophorou et al., 2005). Mice were maintained in accordance with
US NIH guidelines. All animal experiments were approved by the NCI Animal
Care and Use Committee.
Generation of KLH-Specific CD4+ T Cell Clones
Mice were immunized with KLH (Calbiochem) mixed with Alum (Imject Alum,
Pierce) i.p. and 3 weeks later splenocytes were restimulated with KLH
(50 mg/ml) plus irradiated splenocytes. Cells were restimulated with KLH
plus irradiated splenocytes every 10 days to establish KLH-specific CD4+
T cell lines. KLH-specific CD4+ T cell clones were then isolated by limiting dilu-
tion with KLH-APC (irradiated splenocytes) in the presence of recombinant
human IL-2 (10 units/ml). TCR Vb usage of each clone was analyzed by flow
cytometry to identify and select independent clones expressing different
TCR Vb for use in experiments. To maintain KLH-specific CD4+ T cell clones,
cells were restimulated with KLH (50 mg/ml) plus irradiated splenocytes in the
presence of recombinant human IL-2 (10 units/ml) every 10 days. KLH-specific
p53ER-TAM CD4+ T cell clones were similarly established and maintained,
with the exception that 4-hydroxy tamoxifen (4-OHT) (SIGMA) (200 nM) was
added to culture medium every other day. OVA-specific T cell lines were
established by repeated stimulation of OT-II Tg CD4+ T cell with OVA323-339
plus irradiated splenocytes every 10 days.
Preparation of T Cell Populations
To analyze mouse primary CD4+ T cells, naive (CD62LhiCD44lo) or memory
(CD62LloCD44hiCD25) phenotype CD4+ T cells were prepared from spleen
via MACS (CD4+ T cell isolation kit II and CD62L microbeads [Miltenyi]) and/
or flow cytometric cell sorting. To generate OVA-specific memory CD4+
T cells, CD4+ T cells from OVA-specific OT-II TCR Tg mice were utilized.
Naive WT or Trp53/ OT-II CD4+ T cells (CD45.2) were purified and 5 3 105
cells were adoptively transferred (i.v.) to CD45.1 or Rag1/ mice. Recipient
mice were immunized with OVA-alum (i.p.) 1 day after cell transfer. Three to
four weeks later, CD44hiCD62LloCD25 memory phenotype CD4+ T cells
(CD45.2) were isolated by MACS from splenocytes of the immunized mice.
Flow Cytometry
Cells were washed with FACS buffer (HBSS containing 0.2% BSA and 0.05%
Azide) and treated with anti-FcR (24G2), then stained with specific Abs. Anti-
CD3, CD4, CD8, CD25, CD122, CD132, pStat5, pAkt, isotype control Abs,
and AnnexinV-FITC kits were purchased from BD Biosciences. Anti-p53
(1C12)-Alexa647 Ab was purchased from Cell Signaling. Propidium iodide
(PI) was purchased from SIGMA. For pStat5 and pAkt staining, IL-2-stimulated
cells were fixed and permeabilized with 4% paraformaldehyde and ice-cold690 Immunity 40, 681–691, May 15, 2014 ª2014 Elsevier Inc.methanol and acetone solution and incubated with Abs for 1 hr at room
temperature. For p53 staining, cells were fixed and permeabilized with
Foxp3 staining buffer (eBioscience) according to manufacturer’s instructions
and incubated with Ab for 30 min at 4C. Data were collected with FACS
Calibur II, LSR III, or Fortessa (BD Biosciences) and analyzed with FlowJo soft-
ware (Tree Star). Cell sorting was performed with FACS Aria III (BD
Biosciences).
Measurement of T Cell Proliferation
To evaluate fold cell expansion of T cell clones, T cells (1 3 105) were stimu-
lated under the indicated stimulation conditions for 10 days and recovered
live cell number was microscopically counted. Fold expansion was calculated
as (recovered live cell number)/(initial cell number). For cell division analysis,
cells were stained with calboxyfluorescein succinimide ester (CFSE) (Mole-
cular Probes) according to manufacturer’s instructions and analyzed by flow
cytometry. To evaluate the effect of Nutlin3a (Cayman Chemical) on T cell pro-
liferation, Nutlin3a (1.25–5 mM) or ethanol (vehicle control) was added to
cultures.
Immunoblot
Cells were lysed with RIPA buffer (Boston Bioproducts) containing proteinase
inhibitor (Clystalgen). Cell lysate were resolved with NuPAGEBis-Tris SDS-Gel
(Invitrogen) and transferred to 0.2 mm PVDF membrane (Invitrogen).
Membranes were blotted with specific first Ab followed by HRP-conjugated
second Ab. Enhanced chemiluminescence (ECL) (Millipore) was used for
developing. Anti-p53 (1C12) Ab was purchased from Cell Signaling. Anti-
b-actin Ab was purchased from SIGMA and HRP-labeled anti-mouse-IgG
Ab was purchased from Promega.
Quantitative RT-PCR
mRNA was extracted with RNeasy mini kit (QIAGEN). Reverse transcriptase
reaction was performed with SuperScript III First-Strand Synthesis System
(Invitrogen) with Oligo(dT) primer. The synthesized cDNA was subjected to
quantitative PCR with QantiTect SYBR Green PCR kit (QIAGEN). The data
were collected and analyzed with 7900HT Real-Time PCR system (Applied
Biosystems). Primers used for PCR were the following. Trp53-F: 50-ACG
CTTCTCCGAAGACTGG-30, Trp53-R: 50-AGGGAGCTCGAGGCTGATA-30,




Student’s t test with two-tailed distributions was performed for statistical
analyses. p < 0.05 was considered statistically significant.
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